Within every cell of every person is a genetic blueprint. Known as the genome, this blueprint instructs the cell how to respond to its environment, when to reproduce, and when to die.
These genetic blueprints help to explain why each one of us is unique. They also explain why different cells and different patients respond to cancer treatment in different ways—and why one person may respond favorably to a drug, while another may experience debilitating side effects with little or no therapeutic benefit.
At Cell Therapeutics, Inc. (CTI), we use genomic information to develop a personalized approach to cancer therapy with the goal of making standard-of-care treatment less toxic and more effective for individual patients. Our approach is based on matching a drug candidate to a person's genetic profile along with other clinical and diagnostic information to achieve the highest anti-tumor activity, at the lowest dose, and with the fewest side effects. This personalized information can also be used to identify patients for clinical trials who are most likely to respond to the drug candidate.
Significant progress has already been made. Using a personalized approach to guide our drug development and commercialization programs may potentially lower our drug development costs, shorten approval time, and help improve the lives of patients by treating cancer according to each individual's genetic blueprint.
CTI is committed to developing, acquiring, and commercializing innovative treatments for cancer. In our pursuit of making cancer more treatable, we are developing a diversified portfolio of oncology products focused on identifying and developing new, less toxic, and more effective ways to treat cancer.
Our priority and sense of purpose is our customer—the PATIENT. We are reminded daily that there is not a life or a moment to lose. CTI’s patient focus shapes our culture, organization, and values.
Company success is dependent on our EMPLOYEES’ creativity and dedication. Without this talent, commitment, and focus, we would not reach the ambitious goals we set for ourselves.
Our employees are dedicated to TEAMWORK. We have a true sense of ownership for our work and how it is tied directly to products that may significantly improve the outcome of patients’ lives.
We feel a responsibility to give back to our COMMUNITY. We contribute to numerous local organizations and support employee initiatives beyond the workplace.
The “patient first” focus gives us a greater understanding of our market—it is the key to serving our customers well and creating true SHAREHOLDER value. When we are successful in achieving these values, our shareholders will benefit.
Our product pipeline includes next generation drug candidates for some of the leading classes of cancer treatments.
Cutting edge genomic science enables us to target the right drug for the right patient.

CTI Fact Sheet (201K PDF)
We have one product on the market already, two product candidates in phase III clinical development, one in phase II clinical development, and other candidates in preclinical research. Our capabilities span drug discovery, development, and commercialization.